Cigarette smoking, type 2 diabetes mellitus, and glucagon-like peptide-1 receptor agonists as a potential treatment for smokers with diabetes: An integrative review. (March 2019)

• Record Type: Journal Article
• Authors: Yammine, Luba; Kosten, Thomas R.; Pimenova, Maria; Schmitz, Joy M.
• Is Part Of: Diabetes research and clinical practice. Volume 149(2019)
• Page Start: 78
• Page End: 88
• Publication Date: 2019-03
• Subjects: Cigarette smoking -- Smoking cessation treatment -- Type 2 diabetes mellitus -- Glucagon-like peptide-1; CO carbon monoxide -- CPA conditioned place aversion -- CPP conditioned place preference -- CVD cardiovascular disease -- CAD coronary artery disease -- EPM elevated plus maze -- eNOS endothelial nitric oxide synthase -- XR extended release -- GI gastrointestinal -- GLP-1 glucagon-like peptide-1 -- HbA1C glycosylated hemoglobin -- HFD high fat diet -- IL-6 interleukin 6 -- IPN interpeduncular nucleus -- MHb medial habenular -- NRT nicotine replacement therapy -- NAc nucleus accumbens -- NTS nucleus tractus solitarius -- OR odds ratio -- PPG preproglucagon -- RA receptor agonist -- RD regular diet -- RR relative risk -- STZ streptozotocin -- DM type 2 diabetes mellitus -- TUD tobacco use disorder -- TNF-α tumor necrosis factor alpha -- VTA ventral tegmental area; Diabetes -- Periodicals; Diabetes Mellitus -- Periodicals; 616.462
• DOI: 10.1016/j.diabres.2019.01.033
• Languages: English
• ISSNs: 0168-8227

Abstract

Highlights: Cigarette smoking contributes to the macro- and micro-vascular complications of DM. Conventional smoking cessation pharmacotherapy may be less effective in DM smokers. GLP-1 RAs could present a potential treatment for smoking and DM comorbidity. Abstract: Tobacco use disorder (TUD), in particular cigarette smoking, contributes significantly to the macro- and micro-vascular complications of type 2 diabetes mellitus (DM). Persons with DM who regularly use tobacco products are twice as likely to experience mortality and negative health outcomes. Despite these risks, TUD remains prevalent in persons with DM. The objective of this integrative review is to summarize the relationship between TUD and DM based on epidemiological and preclinical biological evidence. We conclude with a review of the literature on the glucagon-like peptide-1 (GLP-1) as a potential treatment target for addressing comorbid TUD in smokers with DM.